Ask AI
ProCE Banner Activity

Optimizing Testing, First-line Treatment, and Supportive Care for Patients With BRAF V600E–Mutant mCRC and mNSCLC

Slideset

Download slides from a live webinar to gain expert perspectives on contemporary management of BRAF V600E–mutant metastatic colorectal cancer and non-small cell lung cancer.

Released: February 12, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Target Audience

This activity is intended for oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with mCRC and/or mNSCLC in community practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest evidence and guideline recommendations for the first-line treatment of patients with BRAF V600E-mutant mCRC and mNSCLC

  • Integrate biomarker testing workflows to improve identification and timely treatment selection for patients with BRAF V600E-mutant mCRC and mNSCLC

  • Implement practical strategies to manage adverse events associated with BRAF-targeted combination therapies through appropriate dose modifications and supportive care

  • Collaborate across multidisciplinary care teams to personalize treatment plans and ensure optimal outcomes for patients with BRAF-mutant mCRC and mNSCLC